ArticleInfection and immunity2001
Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- Identifying immunoreactive proteins in brucellin for enhanced brucellosis diagnosis: a proteomic approach.Frontiers in microbiology · 2025Article
- Intranasal trivalent candidate vaccine elicits broad humoral and cellular immunity against pneumococcal pneumonia.Frontiers in cellular and infection microbiology · 2025Article
- A subunit vaccine based onActa biochimica et biophysica Sinica · 2024Article
- Registered Influenza Viral Vector BasedFrontiers in cellular and infection microbiology · 2021Article
- Proteomics of Brucella.Proteomes · 2020Review
- Simultaneous Immunization with Omp25 and L7/L12 Provides Protection against Brucellosis in Mice.Pathogens (Basel, Switzerland) · 2020Article
- Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors ExpressingBioMed research international · 2020Article
- Role of Kupffer cells in liver injury induced by CpG oligodeoxynucleotide and flucloxacillin in mice.EXCLI journal · 2020Article
- Development of new generation of vaccines forHeliyon · 2018Review
- A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice.Virology journal · 2018Article
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- A Critical Role of Bacterioferritin in Salmonella pullorum-Induced IFN-β Expression in DF-1 Cells.Frontiers in microbiology · 2016Article
- Recent advances in Brucella abortus vaccines.Veterinary research · 2015Review
- Literature Mining and Ontology based Analysis of Host-Brucella Gene-Gene Interaction Network.Frontiers in microbiology · 2015Article
- Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection.Virology journal · 2014Article
- In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate.Iranian journal of basic medical sciences · 2014Article
- Progress inFrontiers in biology · 2013Article
- A history of the development of Brucella vaccines.BioMed research international · 2013Review
- Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.Frontiers in cellular and infection microbiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The P39 and the bacterioferrin (BFR) antigens of Brucella melitensis 16M were previously identified as T dominant antigens able to induce both delayed-type hypersensivity in sensitized guinea pigs and in vitro gamma interferon (IFN-gamma) production by peripheral blood mononuclear cells from infected cattle. Here, we analyzed the potential for these antigens to function as a subunitary vaccine against Brucella abortus infection in BALB/c mice, and we characterized the humoral and cellular immune responses induced. Mice were injected with each of the recombinant proteins alone or adjuvanted with either CpG oligodeoxynucleotides (CpG ODN) or non-CpG ODN. Mice immunized with the recombinant antigens with CpG ODN were the only group demonstrating both significant IFN-gamma production and T-cell proliferation in response to either Brucella extract or to the respective antigen. The same conclusion holds true for the antibody response, which was only demonstrated in mice immunized with recombinant antigens mixed with CpG ODN. The antibody titers (both immunoglobulin G1 [IgG1] and IgG2a) induced by P39 immunization were higher than the titers induced by BFR (only IgG2a). Using a B. abortus 544 challenge, the level of protection was analyzed and compared to the protection conferred by one immunization with the vaccine strain B19. Immunization with P39 and CpG ODN gave a level of protection comparable to the one conferred by B19 at 4 weeks postchallenge, and the mice were still significantly protected at 8 weeks postchallenge, although to a lesser extent than the B19-vaccinated group. Intriguingly, no protection was detected after BFR vaccination. All other groups did not demonstrate any protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.